医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PD-1/PD-L1 Combinations Drive the Development of New Immunotherapies

2015年11月19日 PM11:00
このエントリーをはてなブックマークに追加


 

BOSTON, LONDON & TOKYO

The immuno-oncology agents Keytruda and Opdivo have already transformed the cancer care landscape. Now specialists are pairing them with approved or experimental agents to improve on their already impressive efficacy, according to the “PD-1/PD-L1 Combination Therapies” report from EP Vantage, the editorial arm of market intelligence firm Evaluate Ltd. The EP Vantage analysis has identified over 150 PD-1/PD-L1 combinations currently in clinical development.

Key findings of the PD-1/PD-L1 Combination Therapies report include:

  • More than half of the agents paired with PD-1 and PD-L1 projects are small molecules, chemotherapies and established drugs.
  • Yervoy is the most widely studied monoclonal antibody combination agent.
  • Lung cancer and melanoma remain the two most popular indications for combination products.
  • A number of products including atezolizumab and durvalumab are already being tested in combination, even before achieving approval from the FDA or European Medicines Agency.
  • Older therapies such as oncolytic viruses and vaccines that have so far disappointed as monotherapies might benefit from the combination approach.

“The past couple of years have seen an explosion in clinical studies of the novel checkpoint agents with a variety of other pharmacology approaches, and results from these will soon start to emerge,” said the report’s author and EP Vantage reporter, Jacob Plieth. “These new combination approaches could be vital to sustaining the biotech bull run. As investors’ enthusiasm for the biopharma sector has cooled in recent months, data confirming the additive effect of immuno-oncology combinations could provide important stock catalysts.”

Beyond looking at the clinical impact of these combinations, the report also includes the rationale for combining therapies, the most promising candidates in development, a detailed look at differing company combination strategies and the cost implications of combinations.

The complimentary PD-1/PD-L1 Combination Therapies report based on market intelligence from EvaluatePharma® can be downloaded at www.evaluategroup.com/PD1.

About Evaluate Ltd

Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. Our services include EvaluatePharmaEvaluateClinical Trials and EvaluateMedTech. Our award-winning editorial team, EP Vantage, leverages our strategic analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit www.evaluate.com. On Twitter: @evaluatepharma, @evaluatemedtech, @evaluateJP @epclinicaltrial, @epvantage.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151119005231/en/

CONTACT

Evaluate and EP Vantage (for general questions)
Christine Lindgren,
+1 617-866-3906
christine.lindgren@evaluategroup.com
or
Chempetitive
Group (for U.S. media)
Rachel Wallace, +1 781-775-3640
rwallace@chempetitive.com
or
Instinctif
Partners (for non-U.S. media)
Gemma Howe, +44 (0) 20 7457 2020
evaluate@instinctif.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Foxconn Selects Wisconsin with Commitment to High-Tech Manufacturing
  • GI Dynamics Selects Proven Process Medical Devices as Contract Manufacturer
  • Takeda and BioSurfaces Announce Joint Research Program to Explore Promising Devices to Treat Gastrointestinal Diseases
  • Co-Diagnostics, Inc. Announces Joint Venture in India
  • Optibrium and Bugworks Sign Agreement for StarDrop License